Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Risk Capital_Angel, Venture (VC), Strategic Corporate( CVC), Private Equity (PE), Mergers and Acquisition (M&A) (Trends)
2014: The rise of hospital-backed venture capital funds
Massachusetts General Brigham, formerly, Massachusetts General Hospital (MGH) -#5-US News-(Cancer Center-US New & World Report)
Finance & Acquisitions (Academia): Massachusetts General Brigham, formerly, Massachusetts General Hospital (MGH)

Affinia Therapeutics

Attachments

*Architects: Biotechnology_Genetics, Gene & Cell Therapy Companies
*Industry: Massachusetts
2022: Mass General Brigham Ventures: 5 things to know
Finance & Acquisitions (Academia): Massachusetts General Brigham, formerly, Massachusetts General Hospital (MGH)
Venture Capital: Series B

2021: Affinia Therapeutics Closes $110 Million Series B
2021: Series B financing co-led by EcoR1 Capital and Farallon Capital Management, with Avidity Partners, Casdin Capital, GV (formerly Google Ventures), Octagon Capital, Perceptive Advisors, RA Capital Management, TCG Crossover, and Woodline Partners LP. Existing investors Atlas Venture, F-Prime Capital, Lonza, Mass General Brigham Ventures, and New Enterprise Associates (NEA) also participated
Founded 2019
Gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases
Rick Modi, chief executive officer of Affinia Therapeutics (2021)
The Company’s proprietary platform enables it to methodically engineer novel AAV vectors and regulatory elements to make gene therapies with potentially improved tissue tropism, cell specificity, safety, and yields.
Waltham, Massachusetts